Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.
Kim I, Seong D, Kim B, Lee D, Remaley A, Leach F, Morton R, Kim S. Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway. Cancer Research 2002, 62: 3649-53. PMID: 12097269.Peer-Reviewed Original ResearchConceptsSelective estrogen receptor modulatorsHuman prostate cancer cell line LNCaPAndrogen-independent pathwayProstate cancer cell line LNCaPCancer cell line LNCaPEstrogen receptor modulatorsCell line LNCaPLNCaP cellsER betaReceptor modulatorsAndrogen-sensitive human prostate cancer cell line LNCaPAndrogen-sensitive human prostate cancer cell line LNCaP.Mixed estrogen agonist/antagonistHuman prostate cancer cell line LNCaP.Estrogen agonist/antagonistProstate-specific antigen assaysEffects of raloxifeneProstate cancer cell line LNCaP.Androgen receptor activityPresence of antiandrogensDose-dependent mannerAgonists/antagonistsSelective ER modulatorsAndrogen response elementAntigen assays